I read that the EMA has recommended against the use of Rasilez (sold as Tekturna in the States) in patients with diabetes, but in the US the FDA has only contraindicated its use when combined with ACE inhibitors or ARBs. Is the EMA overly cautious or the FDA not cautious enough? (the latter, IMO..) What does everyone think?
http://www.newsinferno.com/pharmaceuticals/tekturna-label-changes-valturna-market-withdrawal-announced-by-novartis/36884
http://www.newsinferno.com/pharmaceuticals/tekturna-label-changes-valturna-market-withdrawal-announced-by-novartis/36884